Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06449586 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 15, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Phase: Not applicable to Phase 3 Primary completion date: Jun 1, 2025 to Jun 1, 2026 · Trial status: Recruiting to Active, Not Recruiting · Site details revised at 5 of 5 sitesv3 Show 3 more changesShow less
    • Primary completion date: Jun 1, 2025 to Jun 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 5 of 5 sites
  2. Trial status: Not Yet Recruiting to Recruiting Primary endpoint revised · Start date changed from estimate of Jun 1, 2024 to Jul 1, 2024 · Eligibility criteria shortened, about 10 words · 1 morev2 Show 4 more changesShow less
    • Primary endpoint revised
    • Start date changed from estimate of Jun 1, 2024 to Jul 1, 2024
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints revised (2)

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ruijin Hospital
370 trials monitored
See 13 trials at risk
To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.
Trial Details
NCT Number NCT06449586
Lead Sponsor Ruijin Hospital
Conditions Hematologic Malignancy
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov